Trial Profile

A Multi-center, Randomized, Double-Blind, Parallel Comparative, Phase III Study to Evaluate the Efficacy and Safety of Intravenous Infusion of Nemonoxacin Versus Levofloxain in Treating Adult Patients With CAP

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 26 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Aug 2024 Results published in the International Journal of Antimicrobial Agents
16 Oct 2019 According to a TaiGen Biotechnology media release, the company received notice of on-site inspection from Center for Drug Evaluation of NMPA. The inspection will be activated at the end of October.
20 Sep 2019 According to a TaiGen Biotechnology media release, the company received notice of on-site inspection from Center for Drug Evaluation, NMPA for the NDA approval of Taigexyn (Nemonoxacin) intravenous formulation.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com